Novo Nordisk
Europe, Hovedstaden, Denmark, Bagsværd
Description
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Investor Profile
Novo Nordisk has backed more than 18 startups, with 3 new investments in the last 12 months alone. The firm has led 6 rounds, about 33% of its total and boasts 4 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series A, Series C, Series D rounds (top funding stages).
- Majority of deals are located in United States, Denmark, Canada.
- Strong thematic focus on Biotechnology, Health Care, Pharmaceutical.
- Led 2 rounds in the past year.
Stage Focus
- Series A (22%)
- Series C (17%)
- Series D (11%)
- Seed (11%)
- Corporate Round (11%)
- Pre Seed (6%)
- Series Unknown (6%)
- Series E (6%)
- Convertible Note (6%)
- Series B (6%)
Country Focus
- United States (56%)
- Denmark (11%)
- Canada (11%)
- The Netherlands (6%)
- France (6%)
- Germany (6%)
- Belgium (6%)
Industry Focus
- Biotechnology
- Health Care
- Pharmaceutical
- Therapeutics
- Life Science
- Diabetes
- Medical Device
- Medical
- Information Technology
- Clinical Trials
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
